Immune system modulation via increased phagocyte activity

"Immune system modulation via increased phagocyte activity" is not a specific molecule, receptor, or canonical drug target. Instead, it describes a broad immunological strategy aimed at enhancing the function of professional phagocytes—such as macrophages, neutrophils, and dendritic cells—to improve pathogen clearance and immune surveillance. Phagocytes are essential components of the innate immune system. They patrol tissues and blood to identify, engulf (phagocytose), and destroy pathogens like bacteria, viruses, fungi, as well as dead or dying host cells[6][4]. Upon activation by inflammatory mediators or pathogen-associated molecular patterns (PAMPs), these cells increase their microbicidal capacity through upregulation of surface receptors and production of reactive oxygen species[1][2]. After ingesting pathogens or debris, some phagocytes present antigens to lymphocytes to initiate adaptive immunity[4][5]. Therapeutic strategies that modulate this process include drugs that block inhibitory signals on target cells—such as anti-CD47 antibodies in oncology—which allow enhanced recognition and destruction by macrophages[7]. However, non-specific enhancement carries risks such as excessive inflammation or autoimmunity due to loss of tolerance for self-antigens. Because this entry refers to a general biological process rather than a discrete molecular entity with defined structure/function relationships typical for drug targets (e.g., "Fc gamma receptor," "CD47," etc.), it should not be considered a canonical therapeutic target per se. For structured data purposes in pharmacology databases or ontologies focused on drug-target interactions at the molecular level, this entry would be flagged as incorrect/incomplete.

Enhancement of phagocytosis by blocking inhibitory signals on target cells (e.g., anti-CD47 therapy allows phagocytes to recognize and destroy cancer cells)[7]